TY - JOUR
T1 - Vascular tissue engineering
T2 - Towards the next generation vascular grafts
AU - Naito, Yuji
AU - Shinoka, Toshiharu
AU - Duncan, Daniel
AU - Hibino, Narutoshi
AU - Solomon, Daniel
AU - Cleary, Muriel
AU - Rathore, Animesh
AU - Fein, Corey
AU - Church, Spencer
AU - Breuer, Christopher
PY - 2011/4/30
Y1 - 2011/4/30
N2 - The application of tissue engineering technology to cardiovascular surgery holds great promise for improving outcomes in patients with cardiovascular diseases. Currently used synthetic vascular grafts have several limitations including thrombogenicity, increased risk of infection, and lack of growth potential. We have completed the first clinical trial evaluating the feasibility of using tissue engineered vascular grafts (TEVG) created by seeding autologous bone marrow-derived mononuclear cells (BM-MNC) onto biodegradable tubular scaffolds. Despite an excellent safety profile, data from the clinical trial suggest that the primary graft related complication of the TEVG is stenosis, affecting approximately 16% of grafts within the first seven years after implantation. Continued investigation into the cellular and molecular mechanisms underlying vascular neotissue formation will improve our basic understanding and provide insights that will enable the rationale design of second generation TEVG.
AB - The application of tissue engineering technology to cardiovascular surgery holds great promise for improving outcomes in patients with cardiovascular diseases. Currently used synthetic vascular grafts have several limitations including thrombogenicity, increased risk of infection, and lack of growth potential. We have completed the first clinical trial evaluating the feasibility of using tissue engineered vascular grafts (TEVG) created by seeding autologous bone marrow-derived mononuclear cells (BM-MNC) onto biodegradable tubular scaffolds. Despite an excellent safety profile, data from the clinical trial suggest that the primary graft related complication of the TEVG is stenosis, affecting approximately 16% of grafts within the first seven years after implantation. Continued investigation into the cellular and molecular mechanisms underlying vascular neotissue formation will improve our basic understanding and provide insights that will enable the rationale design of second generation TEVG.
KW - Bone marrow derived mononuclear cells
KW - Extracellular matrix
KW - Stem cells
KW - Translational research
KW - Vascular remodeling
KW - Vascular tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=79957739279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957739279&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2011.03.001
DO - 10.1016/j.addr.2011.03.001
M3 - Review article
C2 - 21421015
AN - SCOPUS:79957739279
SN - 0169-409X
VL - 63
SP - 312
EP - 323
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 4
ER -